269 | REAL‐WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH TREATMENT‐NAIVE MANTLE CELL LYMPHOMA IN THE UK, SWEDEN, AND FRANCE
Introduction: First-line (1L) treatment (tx) with chemoimmunotherapy (CIT) combined with autologous stem cell transplantation (ASCT) has yielded high overall response rates (ORRs) in patients (pts) aged < 65 y with mantle cell lymphoma (MCL), but most will eventually experience relapse. Novel targeted tx (eg, Bruton tyrosine kinase inhibitors, rituximab [R], venetoclax) have further improved outcomes for pts with MCL; this changing tx landscape warrants further characterization. Methods: This real-world (RW) retrospective observational study details tx patterns and outcomes of pts with tx-naive MCL in the UK from 2005–2021 using the Hematological Malignancy Research Network registry, in Sweden (SE) from 2006–2018 using the Swedish Lymphoma Register, and in France (FR) from 2018–2022 using the Real-world Data in Lymphoma and Survival in Adults Database. Pts in interventional studies were excluded. Outcomes of interest included 1L overall survival (OS), progression-free survival (PFS), and ORRs. Results: A total of 1983 pts (UK, n = 474; SE, n = 1214; FR, n = 295) received 1L tx. Most were aged ≥ 65 y; baseline characteristics were comparable across cohorts (Table). In the UK, 53/57 (93.0%) pts who received chemotherapy with ASCT were aged < 65 y. In SE, 231/341 (67.7%) pts who received R-Nordic MCL-2 were aged < 65 y. In FR, 86/98 (87.8%) pts who received ASCT were aged < 65 y. In the 1L setting, most pts received CIT; of high-intensity regimens in pts aged < 65 y, the most common in all countries was high-dose cytarabine (HD AraC) ± R. The most common non–high-intensity regimens in pts aged ≥ 65 y were bendamustine (B) ± R in SE and FR; no single non–high intensity regimen was predominant in the UK (Table). In pts receiving 1L tx overall, ORRs ranged from 65.0% to 83.6%, RW median PFS (mPFS) from 2.5 to 4.5 y, and RW median OS (mOS) from 2.9 y to not reached across countries. In the 1L setting, overall tx effectiveness was better in pts aged < 65 y versus those aged ≥ 65 y; tx effectiveness varied by CIT type (Table). A total of 238 (50.2%), 536 (44.2%), and 72 (24.4%) pts on 1L tx received second-line (2L) tx in the UK, SE, and FR, respectively. In the 2L setting, ibrutinib ± R was the most common tx in the UK (47.1%) and FR (55.6%); B ± R was the most common 2L tx in SE (Table). In pts receiving 2L tx overall, ORRs ranged from 34.9% to 55.8%, RW mPFS was ≤ 0.8 y, and RW mOS was ≤ 2.1 y across countries (Table). Progression within 24 mo from start of 1L tx was observed in 271 (57.2%), 260 (21.4%), and 64 (21.7%) pts in the UK, SE, and FR, respectively. Data on tx sequencing and PFS2 will be presented. Conclusions: This RW study outlines MCL tx patterns in 3 European countries. Heterogeneity in cohorts, including differences in observation periods and tx availability, reflects differences in outcomes. CIT was frequently used in the 1L setting, with high attrition and decreased tx effectiveness in the 2L setting, suggesting a need for more efficacious 1L tx. Research funding declaration: Study funded by AstraZeneca Encore Abstract: EHA 2025 Keywords: non-Hodgkin; indolent non-Hodgkin lymphoma Potential sources of conflict of interest: Y. K. Barqawi Employment or leadership position: AstraZeneca Stock ownership: AstraZeneca S. Azzi-Hatem Employment or leadership position: AstraZeneca B. Tessoulin Consultant or advisory role: AbbVie, BMS Honoraria: Lilly, AbbVie Educational grants: ROCHE, AbbVie, Kite Gilead V. Otero Employment or leadership position: AstraZeneca Stock ownership: AstraZeneca M. Jerkeman Honoraria: AbbVie, Lilly, AstraZeneca, Janssen, BMS, Kite/Gilead, Roche
Read more